Ramucirumab for Gastric Cancer

被引：0
|
作者：
Satoh, Taroh [1 ]
机构：
[1] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Suita, Osaka, Japan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw460
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ISY-9-3
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer
    Hayase, Suguru
    Yamada, Leo
    Ujiie, Daisuke
    Nirei, Azuma
    Tada, Takeshi
    Hanayama, Hiroyuki
    Monma, Tomoyuki
    Saze, Zenichiro
    Ohki, Shinji
    Kono, Koji
    FUKUSHIMA JOURNAL OF MEDICAL SCIENCE, 2019, 65 (01) : 6 - 12
  • [22] Therapeutic response to ramucirumab plus folfiri in patients with metastatic gastric cancer
    Rezvani, Hamid
    Haghighi, Shirin
    Ghobakhlou, Mehdi
    Ataei, Elnaz
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2022, 11 (09) : 5166 - 5169
  • [23] Ramucirumab efficacy in first-line gastric and esophageal cancer treatment
    Longo, Federico
    Reguera, Pablo
    Carrato, Alfredo
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S617 - S621
  • [24] Immunological impact of ramucirumab on tumor microenvironment in advanced gastric cancer.
    Togashi, Yosuke
    Tada, Yasuko
    Kotani, Daisuke
    Kawazoe, Akihito
    Doi, Toshihiko
    Nishikawa, Hiroyoshi
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [25] Fulminant Fournier's gangrene in a patient with gastric cancer treated with ramucirumab and paclitaxel
    Rakusic, Zoran
    Krpan, Ana Misir
    Sjekavica, Ivica
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2020, 11
  • [26] Plasma biomarker analysis of ramucirumab in Japanese patients with advanced gastric cancer.
    Takahari, Daisuke
    Wakatsuki, Takeru
    Mashima, Tetsuo
    Chin, Keisho
    Ichimura, Takashi
    Ogura, Mariko
    Matsushima, Tomohiro
    Osumi, Hiroki
    Nakayama, Izuma
    Ota, Yumiko
    Shinozaki, Eiji
    Suenaga, Mitsukuni
    Kawata, Naomi
    Horiike, Yuki
    Seimiya, Hiroyuki
    Fujita, Naoya
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [27] Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer
    Roviello, Giandomenico
    Conca, Raffaele
    D'Angelo, Alberto
    Multari, Andrea Giovanni
    Paganini, Giovanni
    Chiriaco, Giorgio
    Petrioli, Roberto
    Corona, Silvia Paola
    Rosellini, Pietro
    Aieta, Michele
    ANTI-CANCER DRUGS, 2020, 31 (06) : 632 - 636
  • [28] Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices
    Paulson, A. Scott
    Hess, Lisa M.
    Liepa, Astra M.
    Cui, Zhanglin Lin
    Aguilar, Kathleen M.
    Clark, Jamyia
    Schelman, William
    GASTRIC CANCER, 2018, 21 (05) : 831 - 844
  • [29] Is ramucirumab still the only second-line treatment in metastatic gastric cancer?
    El Gharib, Khalil
    Kourie, Hampig Raphael
    PHARMACOGENOMICS, 2020, 21 (17) : 1203 - 1206
  • [30] Ramucirumab in the treatment of refractory metastatic gastric cancer: Results from the RamSelGa trial
    Tryakin, A.
    Perminova, E.
    Stroyakovsky, D.
    Titova, T.
    Yukalchuk, D.
    Ponomarenko, D.
    Beliak, N.
    Teletaeva, G. M.
    Ratner, E.
    Mochalova, A.
    Gordeeva, O. O.
    Meshcheryakov, A.
    Zhabina, A. S.
    Gamayunov, S.
    Smolin, A.
    Povyshev, A.
    Andrievsckih, M.
    Fedyanin, M.
    Tsimafeyeu, I.
    Besova, N.
    ANNALS OF ONCOLOGY, 2019, 30
12345